Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

As Moderna's Market Cap Nears $100 Billion, How Risky Is The Stock?

By Investing.com (Haris Anwar/Investing.com)Stock MarketsJul 15, 2021 09:44AM ET
www.investing.com/analysis/as-modernas-market-cap-nears-100billion-how-risky-is-the-stock-200591531
As Moderna's Market Cap Nears $100 Billion, How Risky Is The Stock?
By Investing.com (Haris Anwar/Investing.com)   |  Jul 15, 2021 09:44AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

After its more than 450% surge during 2020, the meteoric rally in Moderna (NASDAQ:MRNA) shares continues this year. The gains—propelled by the biotech's breakthrough vaccine against COVID-19—have been so powerful that this 11-year-old company is now approaching a market capitalization of $100 billion.

The stock jumped almost 5% on Wednesday, to trade at a record $246.92, before closing at $246.40, valuing the Cambridge, Massachusetts-based Moderna at almost $99 billion.

Moderna Weekly Chart.
Moderna Weekly Chart.

This elevated level of valuation—which puts Moderna in the same league as global pharma giants such as Sanofi (NASDAQ:SNY) and GlaxoSmithKline (NYSE:GSK), also raises an important question: Where do MRNA shares go from here?

The answer to that question very much depends on the path the global health crisis takes and the company’s success at moving beyond vaccines in order to unlock the full potential of mRNA technology, on which the COVID vaccine is based, as a remedy for other diseases. For the time being, analyst predictions for the company's near-term sales potential range widely.

MRNA Consensus Estimates
MRNA Consensus Estimates

According to consensus estimates published on Investing.com, though the majority of analyts polled currently have a buy rating on the stock a significant minority don't hold the same conviction on the biotech.

Moderna, which had nominal sales before the pandemic, could bring in revenue ranging from $13 billion to $22 billion in 2021, according to analysts’ forecasts. But beyond this year, forecasting vaccine sales becomes trickier.

Morningstar analyst Karen Andersen in a Bloomberg report says the vaccine market could top out at $72 billion worldwide this year, and then fall to $65 billion in 2022 and $8 billion the following year.

“The extent of the slide will depend on how many people need booster shots, how often and whether Moderna, Pfizer (NYSE:PFE) and others will be able to raise prices to compensate for a smaller market,” the report says.

Already At Peak Valuation?

Analysts covering biotech companies, which thrive on their first set of products, say that in such cases, companies peak at about 10 times future sales, which they have the potential to fetch in the next three to five years.

Applying this rule to Moderna suggests that the company may have already achieved its peak valuation, and it will be tough for the stock to move higher from these levels. Companies as diverse as Alexion (NASDAQ:ALXN) and Gilead (NASDAQ:GILD) have shown investors a similar path after launching their breakthrough drugs.

Gilead, which launched a ground-breaking hepatitis C drug in late 2013, saw its sales surge to $19 billion in 2015 but then started to decline as competition grew. Gilead's value followed suit, dropping as much as $100 billion from its peak of almost $180 billion.

Long-Term Gilead Chart.
Long-Term Gilead Chart.

Beyond the COVID-19 pandemic, Moderna executives are optimistic their technology will bring cures for other respiratory-infectious diseases, such as respiratory syncytial virus, or RSV; and cytomegalovirus, or CMV; as well as other potential therapies for ailments including cancers and inflammatory diseases.

Betting on other breakthroughs may not bring windfalls as quickly as those fueled by the emergency authorization for the COVID vaccines. Most of Moderna’s experimental vaccines remain in early stage human trials, except its shot for cytomegalovirus. That could turn into a multi-billion-dollar product if it works. Moderna also plans human trials this year of a vaccine against Epstein-Barr virus, which causes mononucleosis.

Bottom Line

Moderna stock has proved a great bet for early investors. Its future path, however, is still uncertain after such a powerful rally which has pushed the stock beyond the fundamentals of future vaccine sales.

As Moderna's Market Cap Nears $100 Billion, How Risky Is The Stock?
 

Related Articles

Fawad Razaqzada
Chart Of The Day: FTSE Breaks Out  By Fawad Razaqzada - Oct 15, 2021 2

This article was written exclusively for Investing.com.Global stocks have surged back higher this week, with the FTSE reaching a new high for the year. The index has not peaked...

As Moderna's Market Cap Nears $100 Billion, How Risky Is The Stock?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (9)
Scott Marcouiller
Scott Marcouiller Jul 17, 2021 11:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This a shallow article lacking detail of Moderna’s pipeline. They have more vaccines/solutions in late stage trials than virtually any other biotech. It has a name brand unparalelled in the sector. To the comment on joining the S&P, that is short-lived phenomena and not a reason to solely invest in stock. If you want to trade, would think about selling mid next week and then re-enter at later point
Susie Sherrard
Susie Sherrard Jul 16, 2021 11:02AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
There was a very informative article in Bloomberg on July 14th titled “Moderna’s Next Act Is Using mRNA vs. Flu, Zika, HIV, and Cancer”. It may give you some more insight on MRNA:-). Hope this helps with your next article on MRNA.
Tee Tee
Tee Tee Jul 16, 2021 9:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
tyr
Lucas Mayorga
Lucas Mayorga Jul 16, 2021 8:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Your article is irresponsible and lacks of indepht research! Didnt u know is joining SP500 and up 7% next morning !!!
Meru Pet
Meru Pet Jul 15, 2021 6:33PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
will join sp500
Jose Tavares
Jose Tavares Jul 15, 2021 5:45PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I think the Moderna Vaccine will bring high yield revenue for this year alone. forecasting this type vaccine will make sales become trickier.
Rafin Sos
Rafin Sos Jul 15, 2021 1:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
hello
Drew Bednar
Drew Bednar Jul 15, 2021 10:34AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It’s the next Biogen !! Over the nxt three yrs expect it’s price to hit 350 when another pipeline hit occurs from this beast. Let the excitement build and the rewards to all mankind be vast !!
michael engel
michael engel Jul 15, 2021 5:53AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
GILD backbone is Feb/ Apr 2014 hi/lo 84.88/63.50. After June 2015 peak, price decayed to the backbone. Exogenous shock will send it down towards the bubble bottom, in stepping stones. The pandemic eliminated 15% of US elderly, US gov ridden with high debt don't need biotech. The gov will blame the other side.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email